National Institute on Drug Abuse; Notice of Closed Meetings, 4629-4630 [2022-01747]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 19 / Friday, January 28, 2022 / Notices
nbsb. Members of the public may
provide written comments or submit
questions for consideration by the NBSB
at any time via email to NBSB@hhs.gov.
Additionally, the NBSB invites
stakeholders to request up to seven
minutes to address the Board in-person
during the meeting. The Board is
interested in hearing from anyone
involved in, or who represents, a
relevant biomedical, biodefense, or
health security industry; serves as
faculty or conducts research at an
academic institution; occupies a
relevant health profession or works for
a hospital system or health care
consumer organization; or who serves in
a relevant state, Tribal, territorial, or
local government agency. Requests to
provide remarks to the NBSB during the
public meeting must be sent to NBSB@
hhs.gov by March 1, 2022. In that
request, please provide the speaker’s
name, title, and position, with a brief
description of the topic that they will
address. The number of speakers and
topics will be based on relevance to the
mission of the NBSB and amount of
time available on the agenda. The
charter of the NBSB may be reviewed on
the ASPR/NBSB website. Topics and
presentations with an obvious
commercial bias, to include any form of
advertising, marketing, or solicitation,
will not be accepted.
FOR FURTHER INFORMATION CONTACT:
CAPT Christopher L. Perdue, MD, MPH,
NBSB Designated Federal Official,
Washington, DC, NBSB@hhs.gov.
Dawn O’Connell,
Assistant Secretary for Preparedness and
Response.
[FR Doc. 2022–01764 Filed 1–27–22; 8:45 am]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jspears on DSK121TN23PROD with NOTICES1
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
VerDate Sep<11>2014
18:03 Jan 27, 2022
Jkt 256001
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2022–1 Phase I: Adjuvant Development for
Vaccines and for Autoimmune and Allergic
Diseases (Topic 105).
Date: February 18, 2022.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G51,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Thomas F. Conway, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G51, Rockville, MD
20852, 240–507–9685, thomas.conway@
nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2022–1 Phase II: Adjuvant Development for
Vaccines and for Autoimmune and Allergic
Diseases (Topic 105).
Date: February 18, 2022.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G51,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Thomas F. Conway, Ph.D.,
Scientific Review Officer, Scientific Review,
Program Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G51, Rockville, MD
20852, 240–507–9685, thomas.conway@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 25, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–01746 Filed 1–27–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
4629
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; NIGMS Review of SuRE First
Applications.
Date: March 22, 2022.
Time: 10:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 45 Center Drive, Bethesda,
MD 20892 (Video Meeting).
Contact Person: Tracy Koretsky, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, MSC 6200, Room 3AN.12F,
Bethesda, MD 20892, 301 594 2886,
tracy.koretsky@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.859, Biomedical Research and
Research Training, National Institutes of
Health, HHS)
Dated: January 24, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–01741 Filed 1–27–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
UE5: Research Education Course in Product
E:\FR\FM\28JAN1.SGM
28JAN1
4630
Federal Register / Vol. 87, No. 19 / Friday, January 28, 2022 / Notices
Development and Entrepreneurship for Life
Science Researchers.
Date: March 3, 2022.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sindhu Kizhakke
Madathil, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5702, sindhu.kizhakkemadathil@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Career Development and Education SEP.
Date: March 7, 2022.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sindhu Kizhakke
Madathil, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5702, sindhu.kizhakkemadathil@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: January 25, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–01747 Filed 1–27–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jspears on DSK121TN23PROD with NOTICES1
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
VerDate Sep<11>2014
18:03 Jan 27, 2022
Jkt 256001
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Interdisciplinary
Molecular Sciences and Training Integrated
Review Group; Emerging Imaging
Technologies in Neuroscience Study Section.
Date: February 24–25, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sharon S. Low, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5104,
MSC 7846, Bethesda, MD 20892, 301–237–
1487, lowss@csr.nih.gov.
Name of Committee: Applied Immunology
and Disease Control Integrated Review
Group; Drug Discovery and Mechanisms of
Antimicrobial Resistance Study Section.
Date: March 1–2, 2022.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Susan Daum, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3202,
Bethesda, MD 20892, 301–827–7233,
susan.boyle-vavra@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Population Sciences and
Epidemiology A.
Date: March 1, 2022.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Annie Laurie McRee,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 100,
Bethesda, MD 20892, (301) 257–2638,
mcreeal@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–RM–
21–025: NIH Faculty Institutional
Recruitment for Sustainable Transformation
(FIRST) Program—FIRST Cohort.
Date: March 2, 2022.
Time: 9:30 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Srikanth Ranganathan,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4214,
MSC 7802, Bethesda, MD 20892, (301) 435–
1787, srikanth.ranganathan@nih.gov.
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Renal/
Urological Small Business Activities.
Date: March 3, 2022.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Santanu Banerjee, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2106,
Bethesda, MD 20892, (301) 435–5947,
banerjees5@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Bioengineering.
Date: March 4, 2022.
Time: 10:00 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Joseph D. Mosca, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5158,
MSC 7808, Bethesda, MD 20892, (301) 435–
2344, moscajos@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: January 24, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–01737 Filed 1–27–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Research
E:\FR\FM\28JAN1.SGM
28JAN1
]]>Agencies
[Federal Register Volume 87, Number 19 (Friday, January 28, 2022)]
[Notices]
[Pages 4629-4630]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01747]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA UE5: Research Education Course in Product
[[Page 4630]]
Development and Entrepreneurship for Life Science Researchers.
Date: March 3, 2022.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific
Review Officer, Scientific Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD
20892, (301) 827-5702, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA Career Development and Education SEP.
Date: March 7, 2022.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific
Review Officer, Scientific Review Branch, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD
20892, (301) 827-5702, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: January 25, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-01747 Filed 1-27-22; 8:45 am]
BILLING CODE 4140-01-P
